Not All 'Good Cholesterol' Is 'Good': Raising HDL Not a Sure Route to ... - Science Daily (press release)

Not All 'Good Cholesterol' Is 'Good': Raising HDL Not a Sure Route to ... Science Daily (press release) "It's been assumed that if a patient, or group of patients, did something to cause their HDL levels to go up, then you can safely assume that their risk of heart attack will go down," said senior author Sekar Kathiresan, director of preventive ... and more »

Study Recommends More People Be Given Statins - RedOrbit

RedOrbit

Study Recommends More People Be Given Statins RedOrbit Doctors took into consideration the patients' age, blood pressure, cholesterol levels and lifestyle in determining the risk in the study. “We've been taught over the years that high cholesterol is the thing that matters; you mustn't have high ... Q&A: The debate over statinsBBC News Meta-analysis confirms benefit of statins in those with no previous history of ...Medical Xpress NHS 'should consider giving statins to healthy people'Myjoyonline.com The Week UK -Doctors Lounge -Yahoo! News UK all 81 news articles »

Endoluminal Barrier Promotes Weight Loss Without Surgery - Medscape

Endoluminal Barrier Promotes Weight Loss Without Surgery Medscape May 18, 2012 (Lyon, France) — A different approach to bariatric treatment appears to be safe and effective in terms of weight loss and improvements in type 2 diabetes mellitus, and the entire procedure takes less than 30 minutes. Jan Willem Greve, MD, ...

Conflicting research raises questions about statins - Greenville News

Conflicting research raises questions about statins Greenville News So when the Greenville internist learned his cholesterol level was 320, putting him at risk, he started taking statins — drugs designed to prevent heart attacks by lowering the level of cholesterol in the blood. “My father missed my high school ... and more »

Santarus Announces Presentation of UCERIS Phase III Extended Use Data at ... - EON: Enhanced Online News (press release)

Santarus Announces Presentation of UCERIS Phase III Extended Use Data at ... EON: Enhanced Online News (press release) SAN DIEGO--(EON: Enhanced Online News)--Santarus, Inc. (NASDAQ: SNTS) today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS ... and more »